Matribhumi Samachar English
Vancouver, British Columbia–(Newsfile Corp. – March 14, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 545,000 incentive stock options (the “Options”) to employees and consultants of the company, including 100,000 to the company’s officers …
Read More »NervGen Pharma to Present at the Virtual Life Science Investor Forum
Vancouver, British Columbia–(Newsfile Corp. – March 5, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be presenting at the Virtual Life Sciences Investor Forum hosted by OTC Markets Group and …
Read More »NervGen Pharma Grants Stock Options
Vancouver, British Columbia–(Newsfile Corp. – February 18, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 627,200 incentive stock options to the company’s employees, including 505,200 to the company’s Officers, exercisable at a price of …
Read More »NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Vancouver, Canada–(Newsfile Corp. – January 29, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on …
Read More »